PARP inhibitors and haematological malignancies—friend or foe?
KA Skelding, LF Lincz - Cancers, 2021 - mdpi.com
Simple Summary PARP inhibitors are a class of orally active drugs that kill a range of cancer
types by inducing synthetic lethality. The usefulness of PARP inhibitors for the treatment of …
types by inducing synthetic lethality. The usefulness of PARP inhibitors for the treatment of …
PARP inhibitors for homologous recombination-deficient prostate cancer
ES Christenson, ES Antonarakis - Expert opinion on emerging …, 2018 - Taylor & Francis
Introduction: Prostate adenocarcinoma represents a leading cause of cancer-related
mortality. Increased emphasis on understanding the molecular basis of prostate cancer has …
mortality. Increased emphasis on understanding the molecular basis of prostate cancer has …
Therapy-related myeloid neoplasms following PARP inhibitors: real-life experience
V Marmouset, J Decroocq, S Garciaz, G Etienne… - Clinical Cancer …, 2022 - AACR
Purpose: To provide insights into the diagnosis and management of therapy-related myeloid
neoplasms (t-MN) following PARP inhibitors (PARPi). Experimental Design: In a French …
neoplasms (t-MN) following PARP inhibitors (PARPi). Experimental Design: In a French …
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY
J Balmaña, PA Fasching, FJ Couch, S Delaloge… - Breast Cancer Research …, 2024 - Springer
Purpose The interim analysis of the phase IIIb LUCY trial demonstrated the clinical
effectiveness of olaparib in patients with germline BRCA-mutated (gBRCAm), human …
effectiveness of olaparib in patients with germline BRCA-mutated (gBRCAm), human …
Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer
Purpose Targeted inhibitors and immunotherapy have entered the treatment landscape of
metastatic prostate cancer. Genomic testing may uncover which patients benefit most from …
metastatic prostate cancer. Genomic testing may uncover which patients benefit most from …
Myeloid malignancies after treatment for solid tumours
GSG Murthy, S Abedin - Best Practice & Research Clinical Haematology, 2019 - Elsevier
The cure rate for several solid tumour malignancies including breast cancers, head and
neck cancers, bone cancers, and sarcoma has improved remarkably with the advent of …
neck cancers, bone cancers, and sarcoma has improved remarkably with the advent of …
RNA interference to enhance radiation therapy: targeting the DNA damage response
RNA interference (RNAi) therapy is an emerging class of biopharmaceutical that has
immense potential in cancer medicine. RNAi medicines are based on synthetic …
immense potential in cancer medicine. RNAi medicines are based on synthetic …
[HTML][HTML] Olaparib induced aplastic anemia in a patient with castrate resistant prostate cancer: A case report
EA Ali, M Jain, A Pokhrel, U Mooppan… - Leukemia Research …, 2024 - Elsevier
Olaparib is (ADP‐ribose) polymerase inhibitor (PARPi), which stops the repair of single-
stranded DNA breaks. This leads to the death of cancer cells with BRCA1/BRCA2 mutations …
stranded DNA breaks. This leads to the death of cancer cells with BRCA1/BRCA2 mutations …
[PDF][PDF] Leukemia Research Reports
EA Ali, M Jain, A Pokhrel, U Mooppan, J chin Wang - researchgate.net
Olaparib is (ADP-ribose) polymerase inhibitor (PARPi), which stops the repair of single-
stranded DNA breaks. This leads to the death of cancer cells with BRCA1/BRCA2 mutations …
stranded DNA breaks. This leads to the death of cancer cells with BRCA1/BRCA2 mutations …